These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28869796)

  • 21. Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Hatano T; Tanaka S; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Jan; 38(1):401-410. PubMed ID: 29277801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.
    Takahashi M; Miki S; Fujimoto K; Fukuoka K; Matsushita Y; Maida Y; Yasukawa M; Hayashi M; Shinkyo R; Kikuchi K; Mukasa A; Nishikawa R; Tamura K; Narita Y; Hamada A; Masutomi K; Ichimura K
    Cancer Sci; 2019 Jul; 110(7):2247-2257. PubMed ID: 31099446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications.
    Cortes J; Schöffski P; Littlefield BA
    Cancer Treat Rev; 2018 Nov; 70():190-198. PubMed ID: 30243063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).
    Geretti E; Leonard SC; Dumont N; Lee H; Zheng J; De Souza R; Gaddy DF; Espelin CW; Jaffray DA; Moyo V; Nielsen UB; Wickham TJ; Hendriks BS
    Mol Cancer Ther; 2015 Sep; 14(9):2060-71. PubMed ID: 26162690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eribulin improves tumor oxygenation demonstrated by
    Bo T; Yasui H; Shiga T; Shibata Y; Fujimoto M; Suzuki M; Higashikawa K; Miyamoto N; Inanami O; Kuge Y
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):821-833. PubMed ID: 34468781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
    Yamamoto J; Murata T; Tashiro Y; Higuchi T; Sugisawa N; Nishino H; Inubushi S; Sun YU; Lim H; Miyake K; Hongo A; Nomura T; Saitoh W; Moriya T; Tanino H; Hozumi C; Bouvet M; Singh SR; Endo I; Hoffman RM
    Anticancer Res; 2020 May; 40(5):2509-2514. PubMed ID: 32366395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.
    Sampson VB; Vetter NS; Zhang W; Patil PU; Mason RW; George E; Gorlick R; Kolb EA
    Oncotarget; 2016 Dec; 7(52):86594-86607. PubMed ID: 27863409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
    Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
    Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Eribulin on Angiogenesis and the Expression of Endothelial Adhesion Molecules.
    Abbona A; Paccagnella M; Astigiano S; Martini S; Denaro N; Ruatta F; Barbieri O; Merlano M; Garrone O
    Anticancer Res; 2022 Jun; 42(6):2859-2867. PubMed ID: 35641280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.
    Laughney AM; Kim E; Sprachman MM; Miller MA; Kohler RH; Yang KS; Orth JD; Mitchison TJ; Weissleder R
    Sci Transl Med; 2014 Nov; 6(261):261ra152. PubMed ID: 25378644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
    Stacchiotti S; Saponara M; Frapolli R; Tortoreto M; Cominetti D; Provenzano S; Negri T; Dagrada GP; Gronchi A; Colombo C; Vincenzi B; Badalamenti G; Zuco V; Renne SL; Collini P; Morosi C; Dei Tos AP; Bello E; Pilotti S; Casali PG; D'Incalci M; Zaffaroni N
    Eur J Cancer; 2017 May; 76():84-92. PubMed ID: 28284173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo.
    Narayan S; Carlson EM; Cheng H; Condon K; Du H; Eckley S; Hu Y; Jiang Y; Kumar V; Lewis BM; Saxton P; Schuck E; Seletsky BM; Tendyke K; Zhang H; Zheng W; Littlefield BA; Towle MJ; Yu MJ
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1634-8. PubMed ID: 21324692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment.
    Kashiwagi S; Tsujio G; Asano Y; Goto W; Takada K; Takahashi K; Morisaki T; Fujita H; Takashima T; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    J Transl Med; 2018 Mar; 16(1):54. PubMed ID: 29523158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
    Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
    Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
    Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
    Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
    Tanaka S; Ishii T; Sato F; Toi M; Itou J
    Biochem Biophys Res Commun; 2020 May; 526(1):154-157. PubMed ID: 32201082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
    Rios-Doria J; Durham N; Wetzel L; Rothstein R; Chesebrough J; Holoweckyj N; Zhao W; Leow CC; Hollingsworth R
    Neoplasia; 2015 Aug; 17(8):661-70. PubMed ID: 26408258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of ferroptosis in eribulin-induced cytotoxicity in ovarian clear cell carcinoma.
    Azumi M; Kusama K; Yoshie M; Nakano S; Tsuru A; Kato T; Tamura K
    Eur J Pharmacol; 2024 May; 971():176544. PubMed ID: 38552939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.